Trials / No Longer Available
No Longer AvailableNCT00636259
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bicalutamide (Casodex) | 150mg |
Timeline
- First posted
- 2008-03-14
- Last updated
- 2008-06-11
Source: ClinicalTrials.gov record NCT00636259. Inclusion in this directory is not an endorsement.